Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kugelmeiers Ltd. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is being processed within 1 distinct art unit. This singular focus implies that the company's current patent efforts are concentrated on a specific innovation rather than a broad array of technologies. Operating within 1 distinct art unit means the company only needs to adapt to the specific examination standards of one administrative group.
Eric Jason Rogers is the busiest examiner for this portfolio, currently overseeing 1 pending office action. This individual is responsible for the entirety of the company's pending office actions. With only 1 distinct examiner involved, the company's prosecution strategy is highly centralized. There are no other examiners or art units to provide a comparative baseline for performance or expectations. Consequently, the outcome of this single pending action will define the company's current success rate in the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034780 | METHOD FOR THE GENERATION OF NEUROSPHERES | ROGERS, ERIC JASON | 27d |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034780 | METHOD FOR THE GENERATION OF NEUROSPHERES | ROGERS, ERIC JASON | 1638 | §112 | Final Rejection | 27d | Pending | May 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKugelmeiers Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Eric Jason Rogers has the most, with 1 of Kugelmeiers Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
